These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 22334770

  • 1. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
    Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012; 7():43-55. PubMed ID: 22334768
    [Abstract] [Full Text] [Related]

  • 3. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
    Kosoglou T, Hubbell J, Xuan F, Cutler DL, Meehan AG, Kantesaria B, Wittmer BA.
    Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M.
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [Abstract] [Full Text] [Related]

  • 6. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C.
    Respir Res; 2020 May 25; 21(1):128. PubMed ID: 32450869
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
    Maspero JF, Nolte H, Chérrez-Ojeda I, P04139 Study Group.
    J Asthma; 2010 Dec 25; 47(10):1106-15. PubMed ID: 20874458
    [Abstract] [Full Text] [Related]

  • 8. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function.
    Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C, P04073 Study Investigators.
    Eur Respir J; 2012 Feb 25; 39(2):279-89. PubMed ID: 21828036
    [Abstract] [Full Text] [Related]

  • 9. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.
    Weinstein SF, Corren J, Murphy K, Nolte H, White M, Study Investigators of P04431.
    Allergy Asthma Proc; 2010 Feb 25; 31(4):280-9. PubMed ID: 20687982
    [Abstract] [Full Text] [Related]

  • 10. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
    Nolte H, Pavord I, Backer V, Spector S, Shekar T, Gates D, Nair P, Hargreave F.
    Respir Med; 2013 May 25; 107(5):656-64. PubMed ID: 23490226
    [Abstract] [Full Text] [Related]

  • 11. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids.
    Nathan RA, Nolte H, Pearlman DS, P04334 Study Investigators.
    Allergy Asthma Proc; 2010 May 25; 31(4):269-79. PubMed ID: 20678306
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF, AUGMENT COPD study investigators.
    Respir Res; 2014 Oct 14; 15(1):123. PubMed ID: 25756831
    [Abstract] [Full Text] [Related]

  • 13. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ, Keating GM.
    Treat Respir Med; 2004 Oct 14; 3(4):247-68. PubMed ID: 15350163
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE.
    Drugs; 2009 Oct 14; 69(5):549-65. PubMed ID: 19368417
    [Abstract] [Full Text] [Related]

  • 15. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma.
    Maspero J, Cherrez I, Doherty DE, Tashkin DP, Kuna P, Kuo WL, Gates D, Nolte H, Chylack LT.
    Respir Med; 2014 Sep 14; 108(9):1355-62. PubMed ID: 25044280
    [Abstract] [Full Text] [Related]

  • 16. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 14; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 17. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
    Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS, Kim K, Miller SD.
    Chest; 2013 Dec 14; 144(6):1795-1802. PubMed ID: 24077095
    [Abstract] [Full Text] [Related]

  • 18. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
    Lipworth BJ, Collier DJ, Gon Y, Zhong N, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 14; 13():2969-2984. PubMed ID: 30310273
    [Abstract] [Full Text] [Related]

  • 19. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
    Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P.
    Int J Chron Obstruct Pulmon Dis; 2014 Dec 14; 9():697-714. PubMed ID: 25045258
    [Abstract] [Full Text] [Related]

  • 20. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 Dec 14; 15():99-106. PubMed ID: 32021148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.